Serac Healthcare, a clinical radiopharmaceutical company specializing in innovative molecular imaging technologies, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualization and diagnosis of superficial peritoneal endometriosis in women aged 16 and older. Fast Track designation is a process designed to facilitate the development and expedite…
TiumBio, a clinical-stage biopharmaceutical company based in South Korea, recently unveiled encouraging findings from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, aimed at alleviating moderate to severe endometriosis-associated pain. This announcement comes on the heels of a successful $12 million funding round, earmarked to advance the company’s clinical pipeline. The Phase 2a trial showcased promising…
Hera Biotech has shared interim findings from its ongoing clinical trial evaluating the MetriDx endometriosis diagnostic test. This trial, aimed at assessing the world’s first molecular, cell-based test for diagnosing and staging endometriosis without surgery, has reached the interim data analysis phase, shedding light on promising outcomes. Based on protocol data from the initial 38 participants enrolled in the 60-patient study, the…
Endometriosis, a condition impacting approximately 1 in 7 Australian females and individuals assigned female at birth (AFAB), presents significant challenges due to its debilitating symptoms and diagnostic complexities. In response to these challenges, the CHARLI app has been introduced in collaboration with Endometriosis Australia, aiming to enhance reproductive health tracking and management, particularly for those living with endometriosis. The initiative was spearheaded…
A recent study by women’s health startup frendo has uncovered alarming statistics revealing that a quarter of women in UK offices feel pressured or shamed into returning to work prematurely after health-related absences. These findings shed light on the pervasive obstacles faced by women in the workplace when dealing with health issues, indicating a significant lack of support and understanding from employers.…
Gynica, a clinical-stage biotech startup focused on women’s health, has announced the initiation of a first-in-human Phase 1 clinical trial for a novel Endometriosis treatment. Led by renowned expert Prof. Felice Petraglia, the study aims to evaluate Gynica’s non-hormonal, intra-vaginal drug candidates using the IntraVag intra-vaginal drug delivery platform. Endometriosis, affecting over 200 million women worldwide, is characterized by the abnormal growth…
A pioneering drug trial has commenced at a UK hospital, marking a significant milestone in the quest for innovative endometriosis treatments. This Phase II research study, led by the Gynaecology and Research and Development team at NNUH, is examining the safety and effectiveness of a novel antibody, AMY109, developed by Chugai Pharmaceutical Co Ltd. Aimed at reversing the debilitating symptoms of endometriosis…
Serac Healthcare, a clinical radiopharmaceutical company, has made a significant stride in the diagnosis of endometriosis. The company has announced the preliminary results from the first patient cohort in the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) study, focusing on the imaging of endometriosis using the innovative agent 99mTc-maraciclatide. These findings are set to be presented at the Society for Reproductive Investigation…
